Management of antithrombotic therapy in atrial fibrilltion patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association, European Association of Percutaneous Cardiovascular Interventions and European Association of Acute Cardiac Care

References

1. Ahmed I., Gertner E., Nelson W.B. et al. Continuing warfarintherapyis superior to interrupting warfarin with or with out bridgingg anticoagulation therapy in patients under going pace maker and defibrillator implantation // Heart Rhythm.– 2010.– Vol. 7.– P. 745–749. 
2. Alexander J.H., Becker R.C., Bhatt D.L. et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial // Circulation.– 2009.– Vol. 119.– P. 2877–2885. 
3. Alexander J.H., Lopes R.D., James S. et al. Apixaban with antiplatelet therapy after acute coronary syndrome // New Engl. J. Med.– 2011.– Vol. 365.– P. 699–708. 
4. Alexander J.H., Lopes R.D., Thomas L. et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial // Eur. Heart J.– 2014.– Vol. 35.– P. 224–232. 
5. Apostolakis S., Sullivan R.M., Olshansky B., Lip G.Y. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 Score // Chest.– 2013.– Vol. 144.– P. 1555–1563.
6. Armstrong M.J., Gronseth G., Anderson D.C. et al. Summary of evidence-based guideline: periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease: report of the Guideline Development Subcommittee of the American Academy of Neurology // Neurology.– 2013.– Vol. 80.– P. 2065–2069. 
7. Azoulay L., Dell’Aniello S., Simon T. et al. The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation // Thromb. Haemost.– 2013.– Vol. 109.– P. 431–439. 
8. Bang C.N., Gislason G.H., Greve A.M. et al. New-onset atrial fibrillation is associated with cardiovascular events leading to death in a first time myocardial infarction population of 89 703 patients with long-term follow-up: a Nationwide Study // J. Am. Heart Assoc.– 2014.– Vol. 3.– P. e000382. 
9. Bernard A., Fauchier L., Pellegrin C. et al. Anticoagulation in patients with atrial fibrillation under-going coronary stent implantation // Thromb. Haemost.– 2013.– Vol. 110.– P. 560–568. 
10. Billett H.H., Scorziello B.A., Giannattasio E.R., Cohen H.W. Low molecular weight heparin bridging for atrial fibrillation: is VTE thromboprophylaxis the major benefit? // J. Thromb. Thrombol.– 2010.– Vol. 30.– P. 479–485. 
11. Bin Abdulhak A.A., Khan A.R., Tleyjeh I.M. et al. Safety and efficacy of interrupted dabigatran for periprocedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis // Europace.– 2013.– Vol. 15.– P. 1412–1420. 
12. Birnie D.H., Healey J.S., Wells G.A. et al. Pacemaker or defibrillator surgery without interruption of anticoagulation // New Engl. J. Med.– 2013.– Vol. 368.– P. 2084–2093. 
13. Bonow R.O., Carabello B.A., Chatterjee K. et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons // Circulation.– 2008.– Vol. 118.– P. e523–e661. 
14. BRAVO-Investigators. Effect of Bivalirudin on Aortic Valve Intervention Outcomes (BRAVO) Study. Presented at Transcatheter Therapeutics Miami Nov 8. 2011. clinical-trial results.org / Slides / BRAVO presentation And Back Up Slides 2.ppt. Last access on November 25, 2013. 
15. Brugaletta S., Martin-Yuste V., Ferreira-Gonza I. et al. Adequate antiplateletre gimen in patients on chronic anti-vitamin K treatment under-going percutaneous coronary intervention // World. J. Cardiol.– 2011.– Vol. 3.– P. 367–373.
16. Buller H.R., Decousus H., Grosso M.A. et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism // New Engl. J. Med.– 2013.– Vol. 369.– P. 1406–1415. 
17. Caballero L., Ruiz-Nodar J.M., Marin F. et al. Oralanticoagulation improves the prognosis of octogenarian patients with atrial fibrillation under going percutaneous coronary intervention and stenting // Age Ageing.– 2013.– Vol. 42.– P. 70–75. 
18. Camm A.J., Lip G.Y., De Caterina R. et al. 2012 focused up date of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation – developed with the special contribution of the European Heart Rhythm Association // Europace.– 2012.– Vol. 14.– P. 1385–1413.
19. Cano O., Munoz B., Tejada D. et al. Evaluation of a new standardized protocol for the perioperative management of chronically anticoagulated patients receiving implantable cardiac arrhythmia devices // Heart Rhythm.– 2012.– Vol. 9.– P. 361–367. 
20. Chan W., Ajani A.E., Clark D.J. et al. Impact of periprocedural atrial fibrillation on short-term clinical outcomes following percutaneous coronary intervention // Am. J. Cardiol.– 2012.– Vol. 109.– P. 471–477. 
21. Chen H.C., Chen Y.L., Guo B.F. et al. Thrombocytopenia, dual antiplatelet therapy, and heparin bridging strategy in-crease pocket hematoma complications in patients undergoing cardiac rhythm device implantation // Can. J. Cardiol.– 2013.– Vol. 29.– P. 1110–1117.
22. Cheng A., Nazarian S., Brinker J.A. et al. Continuation of warfarin during pacemaker or implantable cardioverter-defibrillator implantation: a randomized clinical trial // Heart Rhythm.– 2011.– Vol. 8.– P. 536–540. 
23. Chow V., Ranasinghe I., Lau J. et al. Periprocedural anticoagulation and the incidence of haematoma formation after permanent pacemaker implantation in the elderly // Heart, Lung Circ.– 2010.– Vol. 19.– P. 706–712. 
24. Clemens A., Fraessdorf M., Friedman J. Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment // Vasc. Health Risk Manage.– 2013.– Vol. 9.– P. 599–615. 
25. Connolly S., Pogue J., Hart R. et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial // Lancet.– 2006.– Vol. 367.– P. 1903–1912.
26. Connolly S.J., Eikelboom J., Joyner C. et al. Apixaban in patients with atrial fibrillation // New Engl. J. Med.– 2011.– Vol. 364.– P. 806–817. 
27. Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation // New Engl. J. Med.– 2009.– Vol. 361.– P. 1139–1151.
28. Connolly S.J., Ezekowitz M.D.,Yusuf S. et al. New lyidentified events in the RE-LY trial // New Engl. J. Med.– 2010.– Vol. 363.– P. 1875–1876.
29. Connolly S.J., Wallentin L., Ezekowitz M.D. et al. The LongTerm Multi-Center Observational Study of Dabigatran Treatment in Patients with Atrial Fibrillation: (RELY-ABLE) Study // Circulation.– 2013.– Vol. 128.– P. 237–243.
30. Dans A.L., Connolly S.J., Wallentin L. et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial // Circulation.– 2013.– Vol. 127.– P. 634–640.
31. De Caterina R., Husted S., Wallentin L. et al. General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease // Thromb. Haemost.– 2013.– Vol. 109.– P. 569–579. 
32. De Caterina R., Husted S., Wallentin L. et al. Vitamin K antagonists in heart disease: Current status and perspectives (Section III). Position Paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease // Thromb. Haemost.– 2013.– Vol. 110.– P. 1087–1107. 
33. De Caterina R.D., Husted S., Wallentin L. et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes // J. Am. Coll. Cardiol.– 2013.– Vol. 59.– P. 1413–1425. 
34. Dentali F., Riva N., Crowther M. et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature // Circulation.– 2012.– Vol. 126.– P. 2381–2391.
35. Dewilde W.J., Oirbans T., Verheugt F.W. et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial // Lancet.– 2013.– Vol. 381.– P. 1107–1115.
36. Di Biase L., Burkhardt J.D., Mohanty P. et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio // Circulation.– 2010.– Vol. 121.– P. 2550–2556. 
37. Di Mario C., Eltchaninoff H., Moat N. et al. The 2011–12 pilot European Sentinel Registry of Transcatheter Aortic Valve Implantation: in-hospital results in 4,571 patients // Euro Intervention.– 2013.– Vol. 8.– P. 1362–1371. 
38. Donze J., Rodondi N., Waeber G. et al. Scorestopredict major bleeding risk during oral anticoagulation therapy: a prospective validation study // Am. J. Med.– 2012.– Vol. 125.– P. 1095–1102. 
39. Douketis J.D., Spyropoulos A.C., Spencer F.A. et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines // Chest.– 2012.– Vol. 141.– P. e326S–e350S. 
40. Eikelboom J.W., Connolly S.J., Brueckmann M. et al. Dabigatran versus warfarin in patients with mechanical heart valves // New Engl. J. Med.– 2013.– Vol. 369.– P. 1206–1214. 
41. Fauchier L., Pellegrin C., Bernard A. et al. Comparison of frequency of major advers events in patients with atrial fibrillation receiving baremetal versus drug-eluting stents in their coronary arteries // Am. J. Cardiol.– 2012.– Vol. 110.– P. 7–12. 
42. Faxon D.P., Eikelboom J.W., Berger P.B. et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective // Thromb. Haemost.– 2011.– Vol. 106.– P. 572–584.
43. Figulla H.R., Cremer J., Walther T. Positionspapier zur catheter gefuhrten Aorten klappen intervention // Kardiologie.– 2009.– Vol. 3.– P. 199–206. 
44. Gallagher A.M., Setakis E., Plumb J.M. et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients // Thromb. Haemost.– 2011.– Vol. 106.– P. 968–977.
45. Gallego P., Roldan V, Marin F. et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation // Thromb. Haemost.– 2013.– Vol. 110.– P. 1189–1198.
46. Gao F., Zhou Y.J., Wang Z.J. et al. Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation // Circ. J.– 2010.– Vol. 74.– P. 701–708.
47. Gerson L.B., Michaels L., Ullah N. et al. Adverse events associated with anticoagulation therapy in the periendoscopic period // Gastrointest Endosc.– 2010.– Vol. 71.– P. 1211–1217. 
48. Ghanbari H., Feldman D., Schmidt M. Cardiac resynchronization therapy device implantation in patients with therapeutic international normalized ratios // Pacing. Clin. Electrophysiol.– 2010.– Vol. 33.– P. 400–406. 
49. Gilard M., Blanchard D., Helft G. et al. Antiplatelet therapy in patients with anticoagulant sunder going percutaneous coronary stenting (from STENTIng and oral antiCOagulants[STEN- TICO]) // Am. J. Cardiol.– 2009.– Vol. 104.– P. 338–342. 
50. Gilard M., Eltchaninoff H., Iung B. et al. Registry of transcatheter aortic-valve implantation in high-risk patients // New Engl. J. Med.– 2012.– Vol. 366.– P. 1705–1715. 
51. Giugliano R.P., Ruff C.T., Braunwald E. et al. Edoxaban versus warfarin in patients with atrial fibrillation // New Engl. J. Med.– 2013.– Vol. 369.– P. 2093–2104. 
52. Granger C.B., Alexander J.H., McMurray J.J. et al. Apixaban versus warfarin in patients with atrial fibrillation // New Engl. J. Med.– 2011.– Vol. 365.– P. 981–992.
53. Hakalahti A., Uusimaa P., Ylitalo K., Raatikainen M.J. Catheter ablation of atrial fibrillation in patients with therapeutic oral anticoagulation treatment // Europace.– 2011.– Vol. 13.– P. 640–645. 
54. Hamm C.W., Bassand J.P., Agewall S. et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) // Eur. Heart J.– 2011.– Vol. 32.– P. 2999–3054. 
55. Hansen M.L., Sorensen R., Clausen M.T. et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation // Arch. Internal. Med.– 2010.– Vol. 170.– P. 1433–1441.
56. Hawn M.T., Graham LA., Richman J.S. et al. Riskof major adverse cardiac events following non-cardiac surgery in patients with coronary stents // JAMA.– 2013.– Vol. 310.– P. 1462–1472. 
57. Healey J.S., Eikelboom J., Douketis J. et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial // Circulation.– 2012.– Vol. 126.– P. 343–348. 
58. Heidbuchel H., Verhamme P., Alings M. et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation // Europace.– 2013.– Vol. 15.– P. 625–651. 
59. Ho K.W., Ivanov J., Freixa X. et al. Antithrombotic therapy after coronary stenting in patients with nonvalvular atrial fibrillation // Can. J. Cardiol.– 2013.– Vol. 29.– P. 213–218. 
60. Hohnloser S.H., Camm A.J. Safety and efficacy of dabigatran et exilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature. // Europace.– 2013.– Vol. 15.– P. 1407–1411. 
61. Hohnloser S.H., Oldgren J., Yang S. et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial // Circulation.– 2012.– Vol. 125.– P. 669–676.
62. Holmes D.R. Jr., Mack M.J., Kaul S. et al. ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement // J. Am. Coll. Cardiol.– 2012.– Vol. 59.– P. 1200–1254. 
63. Huber K., Airaksinen K.J., Cuisset T. et al. Antithrombotic therapy in patients with atrial fibrillation under going coronary stenting: similarities and dissimilarities between North America and Europe // Thromb. Haemost.– 2011.– Vol. 106.– P. 569–571.
64. Huber K., Lip G.Y. Differences between ACC/AHA and ESC Guidelines on antiplatelet therapy in patients with acute coronary syndromes // Thromb. Haemost.– 2013.– Vol. 110.– P. 11–13. 
65. Huisman M.V., Lip G.Y., Diener H.C. et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncer-tainties in routine practice // Thromb. Haemost.– 2012.– Vol. 107.– P. 838–847. 
66. Husted S., De Caterina R., Andreotti F. et al. Esc Working Group On Thrombosis Task Force On Anticoagulants In Heart Disease OB. Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel // Thromb. Haemost.– 2014.– Vol. 111.– P. 781–782. 
67. Jaffer A.K., Brotman D.J., Bash L.D. et al. Variations in perioperative warfarin management: outcomes and practice patternsatnine hospitals // Am. J. Med.– 2010.– Vol. 123.– P. 141–150.
68. Kastrati A., Neumann F.J., Mehilli J. et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention // New Engl. J. Med.– 2008.– Vol. 359.– P. 688–696. 
69. Kirchhof P., Ammentorp B., Darius H. et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events — European Registry in Atrial Fibrillation (PREFER in AF) // Europace.– 2014.– Vol. 16.– P. 6–14.
70. Kirchhof P., Breithardt G., Aliot E. et al. Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference // Europace.– 2013.– Vol. 15.– P. 1540–1556. 
71. Kralev S., Schneider K., Lang S. et al. Incidence and severity of coronary artery disease in patients with atrial fibrillation under going first-time coronary angiography // PloS One.– 2011.– Vol. 6.– P. e24964.
72. Krijthe B.P., Kunst A., Benjamin E.J. et al. Projections on the number of individuals with atrial fibril lationin the European Union, from 2000 to 2060 // Eur. Heart J.– 2013.– Vol. 34.– P. 2746–2751.
73. Lahtela H., Rubboli A., Schlitt A. et al. Heparin bridging vs. uninter-rupted oral anticoagulation in patients with Atrial Fibrillation under going Coronary Artery Stenting. Results from the AFCAS registry // Circ. J.– 2012.– Vol. 76.– P. 1363–1368. 
74. Lakkireddy D., Reddy Y.M., Di Biase L. et al. Feasibility and safety of un interrupted rivaroxaban for periprocedural anticoagulationin patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry // J. Am. Coll. Cardiol.– 2014.– Vol. 63.– P. 982–988.
75. Lamberts M., Gislason G.H., Olesen J.B. et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention // J. Am. Coll. Cardiol.– 2013.– Vol. 62.– P. 981–989.
76. Lamberts M., Olesen J.B., Ruwald M.H. et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study // Circulation.– 2012.– Vol. 126.– P. 1185–1193.
77. Lane D., Raichand S., Moore D. et al. Combined anticoagulation and antiplatelet therapy forhigh-risk patients with atrial fibrillation: a systematic review // Health Technol Assess.– 2013.– Vol. 17.– P. 1–188.
78. Larsen T.B., Rasmussen L.H., Skjoth F. et al. Efficacy and safety of dabigatran etexilate and warfarin in ‘real world’ patients with atrial fibrillation: a prospective nation wide cohort study // J. Am. Coll. Cardiol.– 2013.– Vol. 61.– P. 2264–2273. 
79. Lee C.K., Yoo S.Y., Hong M.Y., Jang J.K. Antithrombotic or antiplatelet agents in patients undergoing permanent pacemaker implantation // Korean. Circ. J.– 2012.– Vol. 42.– P. 538–542.
80. Leon M.B., Smith C.R., Mack M. et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery // New Engl. J. Med.– 2010.– Vol. 363.– P. 1597–1607. 
81. Li H.K., Chen F.C., Rea R.F. et al. No increased bleeding events with continuation of oral anticoagulation therapy for patients undergoing cardiac device procedure // Pacing. Clin. Electrophysiol.– 2011.– Vol. 34.– P. 868–874. 
82. Lip G.Y. Recommendation sfor thromboprophylaxis in the 2012 focused up date of the ESC guidelines on atrial fibrillation: acommentary // J. Thromb. Haemost.– 2013.– Vol. 11.– P. 615–626. 
83. Lip G.Y., Bongiorni M.G., Dobreanu D. et al. Novel oral anticoagulants for stroke prevention in atrial fibrillation: results of the European Heart Rhythm Association survey // Europace.– 2013.– Vol. 15.– P. 1526–1532. 
84. Lip G.Y., Haguenoer K., Saint-Etienne C., Fauchier L. Relationship of the SAMe-TT2R2 Score to Poor-Quality Anticoagulation, Stroke, Clinically Relevant Bleeding, and Mortality in Patients With Atrial Fibrillation // Chest. – DOI: 10.1378/ chest.13-2976.
85. Lip G.Y., Huber K., Andreotti F. et al. Management of antithrombotic therapy in atrial fibrillation patients pre- senting with acute coronary syndrome and/or under going percutaneous coronary intervention/stenting // Thromb. Haemost.– 2010.– Vol. 103.– P. 13–28.
86. Lip G.Y., Lane D.A. Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? // Am. J. Med.– 2010.– Vol. 123.– P. 785–789. 
87. Lip G.Y., Laroche C., Dan G.A. et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry // Europace.– 2014.– Vol. 16.– P. 308–319.
88. Lip G.Y., Nieuwlaat R., Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation // Chest.– 2010.– Vol. 137.– P. 263–272. 
89. Lopes R.D., Li L., Granger C.B. et al. Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes // Am. J. Med.– 2012.– Vol. 125.– P. 897–905. 
90. Mahaffey K.W., Stevens S.R., White H.D. et al. Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial // Eur. Heart J.– 2014.– Vol. 35.– P. 233–241. 
91. Mak K.H. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials // B.M.J. Open.– 2012.– Vol. 2.
92. Manzano-Fernandez S., Cambronero F., Caro-Martinez C. et al. Mild kidney disease as a risk factor for major bleeding in patients with atrial fibrillation undergoing percutaneous coronary stenting // Thromb. Haemost.– 2012.– Vol. 107.– P. 51–58.
93. Marin F., Huber K., Lip G.Y. et al. Antithrombotic therapy in atrial fibrillation and stentim-plantation: treatment or threats by theuse of triple or dual antithrombotic therapy // Thromb. Haemost.– 2013.– Vol. 110.– P. 623–625. 
94. McBane R.D., Wysokinski W.E., Daniels P.R. et al. Periprocedural anticoagulation management of patients with venous thromboembolism // Arterioscler. Thromb. Vasc. Biol.– 2010.– Vol. 30.– P. 442–448.
95. Mega J.L., Braunwald E., Mohanavelu S. et al. Group AA-Ts. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial // Lancet.– 2009.– Vol. 374.– P. 29–38.
96. Mega J.L., Braunwald E., Mohanavelu S. et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial // Lancet.– 2009.– Vol. 374.– P. 29–38. 
97. Mega J.L., Braunwald E., Wiviott S.D. et al. Rivaroxaban in patients with a recent acute coronary syndrome // New Engl. J. Med.– 2012.– Vol. 366.– P. 9–19.
98. Mehran R., Baber U., Steg P.G. et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study // Lancet.– 2013.– Vol. 382.– P. 1714–1722. 
99. Mok M., Urena M., Nombela-Franco L. et al. Clinical and prognostic implications of existing and new-onset atrial fibrillation in patients undergoing transcatheter aortic valve implantation // J. Thromb. Thrombolysis.– 2013.– Vol. 35.– P. 450–455. 
100. Mutuberria M., Sambola A. Bosche, Garcia del Blanco B. et al. Outcomes in patients with atrial fibrillation undergoing coronary artery stenting with a low-moderate CHA2DS2-VASc score: do they need anticoagulation? // Eur. Heart J.– 2013.– P. abstract 4093.
101. Ndrepepa G., Neumann F.J., Deliargyris E.N. et al. Bivalirudin versus heparin plus aglycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials // Circ. Cardiovasc. Interv.– 2012.– Vol. 5.– P. 705–712. 
102. Oldgren J., Budaj A., Granger C.B. et al. Dabigatran vs. placebo in patients with acute coronary syn- dromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial // Eur. Heart J.– 2011.– Vol. 32.– P. 2781–2789. 
103. Oldgren J., Wallentin L., Alexander J.H. et al. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis // Eur. Heart J.– 2013.– Vol. 34.– P. 1670–1680.
104. Pasceri V., Patti G., Pristipino C. et al. Safety of drug eluting stents in patients on chronic anticoagulation using long-term single antiplatelet treatment with clopidogrel // Catheter Cardiovasc. Interv.– 2010.– Vol. 75.– P. 936–942. 
105. Patel M.R., Mahaffey K.W., Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation // New Engl. J. Med.– 2011.– Vol. 365.– P. 883–891. 
106. Pilgrim T., Kalesan B., Zanchin T. et al. Impact of atrial fibrillation on clinical outcomes among patients with coronary artery disease undergoing revascularisation with drug-eluting stents // Euro Intervention.– 2013.– Vol. 8.– P. 1061–1071. 
107. Pini R., Faggioli G., Mauro R. et al. Chronic oral anticoagulant therapy in carotid artery stenting: the un-necessity of perioperative bridging heparin therapy // Thromb. Res.– 2012.– Vol. 130.– P. 12–15. 
108. Pisters R., Lane D.A., Nieuwlaat R. et al. Anoveluser-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey // Chest.– 2010.– Vol. 138.– P. 1093–1100.
109. Poli D., Antonucci E., Testa S., Lip G.Y. A prospective validation of the SAME-TT2R2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin // Intern. Emerg. Med.– 2014.– Vol. 9.– P. 443–447.
110. Potpara T.S., Lip G.Y., Dagres N. et al. Management of acute coronary syndrome in patients with non-valvular atrial fibrillation: results of the European Heart Rhythm Association Survey // Europace.– 2014.– Vol. 16.– P. 293–298. 
111. Rubboli A., Colletta M., Valencia J. et al. Periprocedural management and in-hospital outcome of patients with indication for oral anticoagulation undergoing coronary artery stenting // J. Interv. Cardiol.– 2009.– Vol. 22.– P. 390–397. 
112. Rubboli A., Kovacic J.C., Mehran R., Lip G.Y. Coronary stent implantation in patients committed to long-term oral anticoagulation therapy: successfully navigating the treatment options // Chest.– 2011.– Vol. 139.– P. 981–987. 
113. Rubboli A., Magnavacchi P., Guastaroba P. et al. Antithrombotic management and 1-year outcome of patients on oral anticoagulation undergoing coronary stent implantation (from the Registro Regionale Angioplastiche Emilia- Romagna Registry) // Am. J. Cardiol.– 2012.– Vol. 109.– P. 1411–1417.
114. Rubboli A., Schlitt A., Kiviniemi T. et al. One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS Registry // Clin. Cardiol.– 2014.– Vol. 37.– P. 357–364. 
115. Rubboli A., Sciahbasi A., Briguori C. et al. In-hospital management and outcome of patients on warfarin under-going coronary stent implantation: results of the multicenter, prospective WARfarin and coronary STENTing (WAR-STENT) registry // J. Invasive. Cardiol.– 2013.– Vol. 25.– P. 170–176.
116. Ruff C.T., Giugliano R.P., Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials // Lancet.– 2014.– Vol. 383.– P. 955–962. 
117. Ruiz-Nodar J.M., Marin F., Roldan V. et al. Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score? // Circ. Cardiovasc. Intervent.– 2012.– Vol. 5.– P. 459–466. 
118. Saheb K.J., Deng B.Q., Hu Q.S. et al. Triple antithrombotic therapy versus double antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients requiring chronic oral anticoagulation: a meta-analysis // Chin. Med. J. (Engl).– 2013.– Vol. 126.– P. 2536–2542.
119. Sambola A., Ferreira-Gonzalez I., Angel J. et al. Therapeutic strategies after coronary stenting in chronically anticoagulated patients: the MUSICA study // Heart.– 2009.– Vol. 95.– P. 1483–1488. 
120. Sambola A., Montoro J.B., Del Blanco B.G. et al. Dual antiplatelet therapy versus oral anticoagulation plus dual antiplatelet therapy in patients with atrial fibrillation and low-to-moderate thromboembolic risk undergoing coronary stenting: design of the MUSICA-2 randomized trial // Am. Heart J.– 2013.– Vol. 166.– P. 669–675.
121. Sarafoff N., Martischnig A., Wealer J. et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation // J. Am. Coll. Cardiol.– 2013.– Vol. 61.– P. 2060–2066. 
122. Schlitt A., Rubboli A., Airaksinen K.E., Lip G.Y. Antiplatelet therapy and anticoagulants // Lancet.– 2013.– Vol. 382.– P. 24–25. 
123. Schlitt A., Rubboli A., Lip G.Y. et al. The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: in-hospital-data from the atrial fibrillation under going coronary artery stenting study // Cathet. Cardiovasc. Interv.– 2013.– Vol. 82.– P. E864–E870.
124. Smith C.R., Leon M.B., Mack M.J. et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients // New Engl. J. Med.– 2011.– Vol. 364.– P. 2187–2198. 
125. Smith J.G., Wieloch M., Koul S. et al. Triple antithrombotic therapy follow in ganacute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score // EuroIntervention.– 2012.– Vol. 8.– P. 672–678.
126. Smoyer-Tomic K., Siu K., Walker D.R. et al. Anticoagulant use, the prevalence of bridging, and relation to length of stay among hospitalized patients with non-valvular atrial fibrillation // Am. J. Cardiovasc. Drugs.– 2012.– Vol. 12.– P. 403–413. 
127. Stabile E., Sorropago G., Pucciarelli A. SAT-TAVI Investigators. SAT-TAVI (Single Antiplatelet TherapyforTAVI) study: a randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation // J. Am. Coll. Cardiol.– 2011.– Vol. 58.– P. B218. 
128. Steg P.G., James S.K., Atar D. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation // Eur. Heart J.– 2012.– Vol. 33.– P. 2569–2619. 
129. Steib A., Barre J., Mertes M. et al. Can oral vitamin K before elective surgery substitute for preoperative heparin bridging in patients on vitamin K antagonists? // J. Thromb. Haemost.– 2010.– Vol. 8.– P. 499–503. 
130. Stettler C., Wandel S., Allemann S. et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis // Lancet.– 2007.– Vol. 370.– P. 937–948. 
131. Tafur A.J., McBane R., Wysokinski W.E. et al. Predictors of major bleeding in peri-procedural anticoagulation management // J. Thromb. Haemost.– 2012.– Vol. 10.– P. 261–267. 
132. Tamburino C., Ussia G.P., Maisano F. et al. Percutaneous mitral valve repair with the MitraClip system: acute results from a real world setting // Eur. Heart J.– 2010.– Vol. 31.– P. 1382–1389.
133. Tompkins C., Cheng A., Dalal D. et al. Dual antiplatelet therapy and heparin ‘bridging’ significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation // J. Am. Coll. Cardiol.– 2010.– Vol. 55.– P. 2376–2382. 
134. Turpie A.G., Kreutz R., Llau J. et al. Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor // Thromb. Haemost.– 2012.– Vol. 108.– P. 876–886.
135. UchidaY., Mori F., Ogawa H. et al. Impactofanticoagulanttherapy with dual antiplatelet therapy on prognosis after treatment with drug-eluting coronary stents // J. Cardiol.– 2010.– Vol. 55.– P. 362–369.
136. Uchino K., Hernandez A.V. Dabigatran association with higher risk of acute coronary events: meta-analysis of non-inferiority randomized controlled trials // Arch. Intern. Med.– 2012.– Vol. 172.– P. 397–402. 
137. Ussia G.P., Scarabelli M., Mule M. et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation // Am. J. Cardiol.– 2011.– Vol. 108.– P. 1772–1776. 
138. Vahanian A., Alfieri O. Guidelines on valvular heart disease in clinical practice // Euro Intervention.– 2013.– Vol. 9.– P. S11–S13. 
139. Vahanian A., Alfieri O., Andreotti F. et al. Guidelines on the management of valvular heart disease (version 2012) // Eur. Heart J.– 2012.– Vol. 33.– P. 2451–2496.
140. Webb J., Rodes-Cabau J., Fremes S. et al. Transcatheter aortic valve implantation: a Canadian Cardiovascular Society position statement // Can. J. Cardiol.– 2012.– Vol. 28.– P. 520–528. 
141. Wenaweser P., Rey C., Eberli F.R. et al. Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome // Eur. Heart J.– 2005.– Vol. 26.– P. 1180–1187.
142. Whitlock R.P., Sun J.C, Fremes S.E. et al. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines // Chest.– 2012.– Vol. 141.– P. e576S–e600S. 
143. Zhao H.J., Zheng Z.T., Wang Z.H. et al. ‘Triple therapy’ rather than ‘triple threat’: a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment // Chest.– 2011.– Vol. 139.– P. 260–270.